Additionally, inhibition of IL-33 with neutralizing antibodies resulted in reduced pathology in experimental autoimmune encephalomyelitis and MRL/lpr mouse models (78, 79). The gene discussed is IL33; the disease is experimental autoimmune encephalomyelitis.